Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Holders of 5% or more of ALLO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Allogene Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Citadel Advisors LLC | 13G | 6.10%13.3M shares | New | Jul 16, 20251 filing | Jul 16, 2025 | SEC |
| Belldegrun Arie | 13G/A | 5.60%12.7M shares | −0.10 ppfrom 5.70% | Feb 13, 20254 filings | Nov 13, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 5.30%11.5M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Lynx1 Capital Management LP | 13G | 5.20%10.9M shares | New | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
15 Schedule 13D and 13G filings on Allogene Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 20257:09 PM ET | Belldegrun Arieand 5 others | 13G/A | 5.60%12.7M shares | −0.10 ppfrom 5.70% | Sep 30, 2025 | SEC |
| Nov 13, 20257:06 PM ET | Capital World Investors | 13G/A | 0.00%0 shares | −5.60 ppfrom 5.60%Below 5% | Sep 30, 2025 | SEC |
| Nov 12, 20254:37 PM ET | Chang David Dand 3 others | 13G/A | 4.90%11.2M shares | −0.10 ppfrom 5.00%Below 5% | Sep 30, 2025 | SEC |
| Aug 12, 20254:57 PM ET | Belldegrun Arieand 5 others | 13G/A | 5.70%12.6M shares | 0.00 ppfrom 5.70% | Jun 30, 2025 | SEC |
| Aug 8, 20258:13 PM ET | Chang David Dand 3 others | 13G/A | 5.00%11.1M shares | 0.00 ppfrom 5.00% | Jun 30, 2025 | SEC |
| Jul 16, 20256:02 PM ET | Citadel Advisors LLCand 6 others | 13G | 6.10%13.3M shares | New | Jul 9, 2025 | SEC |
| May 13, 202511:44 AM ET | Capital World Investors | 13G | 5.60%12.3M shares | New | Mar 31, 2025 | SEC |
| May 9, 20255:49 PM ET | Chang David Dand 3 others | 13G/A | 5.00%11.0M shares | −0.10 ppfrom 5.10% | Mar 31, 2025 | SEC |
| May 9, 20255:30 PM ET | Belldegrun Arieand 5 others | 13G/A | 5.70%12.5M shares | −0.10 ppfrom 5.80% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 5.30%11.5M shares | – | Mar 31, 2025 | SEC |
| Mar 7, 202510:01 AM ET | FMR LLCand 1 other | 13G/A | 4.90%10.2M shares | −6.40 ppfrom 11.30%Below 5% | Feb 28, 2025 | SEC |
| Feb 14, 20259:02 AM ET | Lynx1 Capital Management LPand 1 other | 13G | 5.20%10.9M shares | New | Dec 31, 2024 | SEC |
| Feb 13, 20254:31 PM ET | Belldegrun Arieand 5 others | 13G/A | 5.80%12.4M shares | – | Dec 31, 2024 | SEC |
| Feb 13, 20254:29 PM ET | Chang David Dand 3 others | 13G/A | 5.10%10.9M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20259:16 AM ET | FMR LLCand 1 other | 13G/A | 11.30%23.8M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Allogene Therapeutics, Inc. shares.
No Form 144 notices for Allogene Therapeutics, Inc. are on file.